2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Biological Therapies, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, CHIP, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5521 Multicenter real-world data of asciminib as second-line therapy in chronic myeloid leukemia treatment

Maria Perusini, MD, Msc, Flavia Patino2, Christopher Hillis, MD3, Pierre Laneuville, MD4, Salam Al-Kindi, MD5, Muna Al Rasheed, md6, Naeem Chaudhri, MD7, Muhned Alhumaid, MD, MBBS8, Delphine Rea, MD, PhD9, Hassan Sibai, MD, Msc, BSc10, Dennis Dong Hwan Kim, MD, PhD11
1 Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
2 Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
3 Juravinski Cancer Centre, Hamilton, Canada
4 McGill University Health Centre (MUHC), Montreal, Canada
5 Sultan Qaboos University, Muscat, Oman
6 Kuwait Cancer Control Center, Kuwait City, Kuwait
7 King Faisal Specialist Hospital & Research Centre Riyadh, Riyadh, Saudi Arabia
8 King Fahad Medical City, Riyadh, Saudi Arabia
9 Hôpital Saint-Louis, Paris, France
10 Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
11 Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

Background:
Asciminib (ASC), a STAMP inhibitor that targets the ABL myristoyl pocket, has been approved after failure of ≥2 prior tyrosine kinase inhibitors (TKIs) based on the ASCEMBL trial, and as first-line therapy based on the ASC4FIRST trial. However, its role as a second-line treatment remains less well defined, particularly in the regions, where ASC has not been approved for earlier lines of therapy. We present real-world outcomes of patients who received ASC as second-line therapy across multiple countries.

Aims
To describe the clinical characteristics and outcomes of patients treated with ASC as second-line therapy.

Methods
We retrospectively analyzed 50 patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with ASC as second-line therapy across five countries (Canada, Oman, Kuwait, Saudi Arabia, and France). The primary endpoints were the rates of major molecular response (MMR; BCR: ABL1 <0.1% IS) and MR4 (BCR: ABL1 <0.01% IS) at 12 months. Event-free survival (EFS) was defined as the time from ASC initiation to the earliest occurrence of any of the following events: (1) treatment failure according to ELN 2020 criteria; (2) confirmed loss of MMR on two consecutive assessments; (3) progression to accelerated phase (AP) or blast crisis (BC); (4) death from any cause; or (5) treatment discontinuation. Patients without an event were censored at the date of last follow-up.

Results:
The median age at diagnosis was 57 years (range, 44–65), and 27 patients (54%) were female. Sokal risk at diagnosis was low in 18 (37.5%), intermediate in 20 (41.7%), and high in 10 (20.8%) patients. Six patients had a history of cardiovascular disease.

First-line TKIs included dasatinib (n=16, 32%), nilotinib (n=19, 38%), and imatinib (n=15, 30%). Reasons for first-line TKI discontinuation were 1) resistance/progression (n=22; 47.7%) including resistance in chronic phase (n=12, 26%), suboptimal response with intolerance (n=7, 15.2%), progression (n=3, 6.5%); 2) intolerance with optimal molecular response (n=18, 39.1%), and 3) other reasons (n=6).

At ASC initiation, 10 patients (20%) had BCR: ABL1 ≥10% IS, whereas 16 (32%) were already in MMR or deeper response. Four patients harbored ABL1 kinase domain mutations (F486S, E255K, F359I, and one compound T315I/F359I mutation), and one patient had additional chromosomal abnormalities. The median ASC dose was 80 mg daily (range, 40-400 mg).

With a median follow-up of 512 days (IQR, 300-815), the cumulative 12-month MMR rate was 75.2% (95% CI [61.2–88.6]). Excluding patients already in MMR at ASC initiation, the cumulative 12-month MMR rate was 76.9% [59.8-90.5]. The cumulative 12-month MR4 rate was 43.6% [27.3–58.2]. Estimated EFS was 92.5% at 1 year and 88.1% at 2 years.

Patients with a baseline BCR: ABL1 level <10% tended to have higher 12-month MMR rates than those with BCR: ABL1 ≥10% (82.5% vs. 46.7%; P=0.073). A numerically higher 12-month MMR rate was observed in patients previously treated with imatinib (90.0%) compared with those treated with a second-generation TKI (64.7%); however, this difference was not statistically significant (P = 0.35). Likewise, cardiovascular risk factors did not affect MMR (75.0% vs. 66.7% at 12-month; p=0.88).

In multivariable Cox regression analysis, baseline BCR: ABL1 ≥10% was associated with a trend toward a lower likelihood of achieving MMR (HR 0.37, [0.14-1.04]; P=0.06), with borderline statistical significance.

At the last follow-up, six patients (12%) had discontinued ASC: three because of intolerance despite optimal response, one because of resistance in chronic phase, and two for other reasons (one during an attempt at treatment-free remission and one following progression to IDH-mutated acute myeloid leukemia without detectable BCR: ABL1).

Conclusion
As expected, ASC demonstrated high rates of molecular response, durable EFS, and tolerability as second-line therapy in this multinational real-world cohort. These findings support ASC as an effective second-line treatment option for patients with CML-CP, particularly in settings where access to ASC is available.

Maria Perusini, MD, Msc: Novartis - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony)